Pneumococcal Vaccine
- PMID: 29939571
- Bookshelf ID: NBK507794
Pneumococcal Vaccine
Excerpt
The advent of pneumococcal vaccines has proven to be a significant advancement in treating and preventing a widespread and sometimes deadly disease process. The pneumococcal conjugate vaccines are recommended differently depending on the patient population. While both vaccine types are proven to stimulate long-lasting antibodies in immunocompromised adults, conjugate vaccines have been shown to provide some additional benefits, as will be covered here. This activity describes the mode of action of pneumococcal vaccines, including methods of administration, formulations, adverse event profiles, eligible patient populations, and monitoring, and highlights the role of the interprofessional team in the management of these patients.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
Similar articles
-
Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.Expert Rev Vaccines. 2023 Jan-Dec;22(1):1008-1021. doi: 10.1080/14760584.2023.2273892. Epub 2023 Nov 2. Expert Rev Vaccines. 2023. PMID: 37872765
-
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.Vaccine. 2013 Aug 2;31(35):3577-84. doi: 10.1016/j.vaccine.2013.04.085. Epub 2013 May 18. Vaccine. 2013. PMID: 23688526 Clinical Trial.
-
[Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].Orv Hetil. 2014 Dec 14;155(50):1996-2004. doi: 10.1556/OH.2014.30070. Orv Hetil. 2014. PMID: 25481502 Hungarian.
-
A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.Expert Rev Vaccines. 2022 Feb;21(2):201-214. doi: 10.1080/14760584.2022.2012455. Epub 2022 Feb 3. Expert Rev Vaccines. 2022. PMID: 34882050
-
Pneumococcal conjugate vaccine for young children.Manag Care. 2000 Sep;9(9):49-52, 54, 56-7 passim. Manag Care. 2000. PMID: 11116663 Review.
References
-
- Marijam A, Olbrecht J, Ozakay A, Eken V, Meszaros K. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children. Value Health Reg Issues. 2019 Sep;19:34-44. - PubMed
-
- Huang J, Luo S, Huang M, Zhang T, Min Z, Liu C, Zhang Q, Yang J, Min X. Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein. Microb Pathog. 2019 Apr;129:206-212. - PubMed
-
- Ozlu T, Bulbul Y, Aydin D, Tatar D, Kuyucu T, Erboy F, Koseoglu HI, Anar C, Sunnetcioglu A, Gulhan PY, Sahin U, Ekici A, Duru S, Ulasli SS, Kurtipek E, Gunay S, RIMPACT Study Investigators Immunization status in chronic obstructive pulmonary disease: A multicenter study from Turkey. Ann Thorac Med. 2019 Jan-Mar;14(1):75-82. - PMC - PubMed
-
- Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL, ACIP Pneumococcal Vaccines Work Group. CDC Contributors Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1174-1181. - PubMed
Publication types
LinkOut - more resources
Full Text Sources